Get informed when a big investor buys or sells
+ FollowUndervalued by 49.8% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $1.92 Billion |
|---|---|
| Enterprise Value | $2.92 Billion |
| Annual dividend | $1.01 |
| Dividend yield | 2.50% |
| Earnings per Share | $2.46 |
| Beta | 0.85 |
| Outstanding Shares | 49,540,810 |
| P/E Ratio | 14.04 |
|---|---|
| PEG | -35.66 |
| Price to Sales | 1.69 |
| Price to Book Ratio | 3.53 |
| Enterprise Value to Revenue | 2.48 |
| Enterprise Value to EBIT | 11.83 |
| Enterprise Value to Net Income | 22 |
| Total Debt to Enterprise | 0.38 |
| Debt to Equity | 1.99 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Dermapharm Holding SE, alongside its group companies, specializes in the off-patent branded pharmaceutical market, serving both German and international clients. The company’s operations are organized into three primary divisions: Brande...